XML 48 R31.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue
 12 Months Ended
Dec. 31, 2025
Revenue  
Revenue

24.Revenue

Revenue consists of ASC 606 and ASC 842 revenue. The Group’s revenues, net of value-added tax, disaggregated by revenue source are as follows:

​

​

​

​

​

​

​

​

​

​

​

​

For the Years Ended December 31,

​

​

2023

​

2024

​

2025

​

2025

​

  ​ ​ ​

RMB

  ​ ​ ​

RMB

  ​ ​ ​

RMB

  ​ ​ ​

US$

ASC 606 revenue:

​

  ​

​

  ​

​

  ​

​

  ​

Management and technical support

​

23,164

​

5,196

​

10,206

​

1,459

Medical solution

​

178,442

​

99,158

​

70,239

​

10,044

Medical service

​

218,595

​

188,101

​

294,184

​

42,068

Medicine income

​

100,464

​

82,145

​

79,699

​

11,397

ASC 606 revenue

​

520,665

​

374,600

​

454,328

​

64,968

ASC 842 revenue:

​

​

​

​

​

​

​

​

Operating lease income*

​

13,371

​

6,719

​

3,159

​

452

Sales-type lease income*

 

3,366

​

2,637

​

3,026

​

432

Direct financing lease income*

 

—

​

—

​

—

​

—

ASC 842 revenue

 

16,737

​

9,356

​

6,185

​

884

Total revenue

​

537,402

​

383,956

​

460,513

​

65,852

*

Operating lease income, sales-type lease income and direct financing lease income were recognized under ASC 842, Leases.

​

Contract balance

When either party to a revenue contract has performed, the Group presents the contract in the consolidated balance sheet as a contract asset or a contract liability, depending on the relationship between the Group’s performance and the customer’s payment. The Group merely incurs costs to obtain a contract with a customer. The Group presents any unconditional rights to consideration separately as a receivable. The Group has no contract assets as of December 31, 2024 and 2025, respectively.

The Group’s contract liabilities primarily relate to unsatisfied performance obligations when payment has been received from customers before the Group’s products or services are delivered and are recorded as “Advances from customers” within “Accrued expenses and other liabilities” (note 17) on the consolidated balance sheets. Advance from customers amounted to RMB46,151 and RMB95,698 (US$13,685) as of December 31, 2024 and 2025, respectively. The amount of revenue recognized during the years ended December 31, 2023, 2024 and 2025 that was previously included in the contract liabilities balance as of December 31, 2022, 2023 and 2024 were RMB61,087, RMB28,013 and RMB19,192 (US$2,744), respectively.